Skip to main content

Table 1 Intervention description

From: The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19): study protocol for an investigator-driven randomized controlled clinical trial in primary health care—COLCHICOVID study

Groups

Interventions

Experimental group

Colchicine plus symptomatic treatment (paracetamol)

Patients in this arm will receive study medication colchicine 0.5 mg orally (PO) twice, daily for the first 3 days and then once daily for the last 18 days. If a dose is missed, it should not be replaced.

All patients should also receive the best symptomatic treatment (mainly paracetamol), based on clinical practice.

Control group

Symptomatic treatment

Symptomatic treatment (paracetamol or best symptomatic treatment) based on doctor recommendations.